DOD Vision, Translational Research Award | W81XWH 21 VRP TRA

FAQs: DOD Vision, Translational Research Award (FY21 VRP TRA)

1) What is the DOD Vision, Translational Research Award (FY21 VRP TRA)?

The FY21 VRP TRA is a U.S. Department of Defense funding opportunity focused on advancing vision-related research beyond early discovery and toward practical clinical use, particularly for eye injuries and visual dysfunction linked to military-relevant traumatic events.

2) What is the main goal of this award?

The central goal is translational impact: moving promising findings toward real-world tools or approaches that can prevent, diagnose, reduce, or treat trauma-related eye injuries and visual dysfunction in a way that could ultimately be used in clinical settings.

3) What types of research does this award emphasize?

This award emphasizes development-oriented, translation-focused work rather than basic science in isolation. Projects are expected to show a credible pathway from discovery to something clinically actionable, such as a product or a change in clinical practice.

4) Is basic research eligible under this program?

Based on the description provided, the program is not centered on supporting basic science in isolation. It prioritizes research that is structured to move beyond proof-of-concept and toward clinical readiness and real-world implementation.

5) What kinds of outcomes is the program looking for?

The opportunity highlights outcomes such as new drugs, medical devices, or clinical practice guidelines. The common thread is that the work should be positioned to mature toward definitive testing in clinical trials.

6) Does the proposed work need to be ready for clinical trials?

The program expects proposals to be built around the concrete steps needed to reach clinical readiness, with an aim of becoming ready for definitive testing in clinical trials. The work should not stop at proof-of-concept alone.

7) What does "translational" mean in the context of this award?

In this context, translational means taking a promising discovery and actively developing it toward practical clinical use. This includes steps like validation, optimization, and planning that support movement into regulated human testing where applicable.

8) Is there a focus on trauma related to military service?

Yes. The award targets eye injuries and visual dysfunction that arise from traumatic events relevant to service members, with a focus on conditions tied to military-relevant trauma.

9) What is meant by a "clear and believable pathway" from discovery to clinical outcome?

The program expects applicants to outline a realistic, step-by-step plan that connects earlier findings to a tangible endpoint (for example, a drug, device, or clinical guideline), including the development and validation work needed to move toward clinical trials.

10) What is the role of FDA alignment in this program?

A major feature is strong alignment with U.S. Food and Drug Administration (FDA) requirements when a project involves a regulated product. The program anticipates that regulated-product projects will incorporate regulatory strategy from the start.

11) When is an IND or IDE expected?

If the project involves a regulated drug or device, the opportunity anticipates submission of an Investigational New Drug (IND) application and/or an Investigational Device Exemption (IDE) application during the project period or by the end of the period of performance.

12) Do applicants need regulatory expertise on the team?

Yes. Applicants are expected to include at least one collaborator with real expertise in FDA regulatory pathways so that regulatory planning, documentation expectations, and strategy are integrated into the project from the beginning.

13) Why does the award require FDA regulatory pathway expertise?

The stated intent is to reduce the risk that a technically promising concept stalls due to gaps in documentation, study design, quality considerations, or regulatory framing needed to advance into clinical trials.

14) What agency is issuing the opportunity?

The opportunity is issued by the Department of Defense, Department of the Army, through USAMRAA.

15) What is the funding opportunity number?

The funding opportunity number listed is W81XWH 21 VRP TRA.

16) What is the CFDA number associated with this opportunity?

The opportunity is listed under CFDA 12.420.

17) What kind of funding instrument is used?

The mechanisms listed are cooperative agreements and grants. This indicates awards may involve varying degrees of agency involvement depending on the specific instrument used.

18) What does "discretionary" mean here?

The opportunity is categorized as discretionary, meaning it is a competitively awarded government funding opportunity rather than an entitlement-style program, based on the information provided.

19) Who is eligible to apply?

Eligibility is described as unrestricted, meaning it is broadly open to many entity types, subject to any additional eligibility details that may be provided in the full announcement text.

20) How many awards are expected?

The posting indicates an expected single award.

21) What is the award ceiling (maximum funding amount)?

The award ceiling is listed as 0 in the summary record, which typically suggests the maximum amount was not specified in the summary and would need to be confirmed in the full solicitation materials.

22) When was this opportunity created and when did it close?

The opportunity was created on May 14, 2021, with an original closing date of November 16, 2021.

23) What types of projects are the best fit for this opportunity?

Based on the description, the best-fit projects are later-stage, translation-focused vision trauma efforts with a defined product-development or clinical-implementation trajectory and strong regulatory preparedness (including IND/IDE planning when relevant).

24) Does the program support development of clinical practice guidelines?

Yes. The opportunity explicitly includes clinical practice guidelines as an example of an outcome, alongside drugs and devices, as long as the project has a clear translational pathway toward clinical use.

25) What level of maturity is implied by "ready for definitive testing in clinical trials"?

The description implies a relatively advanced stage of development, where the project has progressed beyond proof-of-concept and includes the validation, optimization, and translational planning needed to support clinical trial readiness and, where applicable, regulated submission steps.